Design: Multicenter, randomized, double-blind, phase 2
Statutes: Recruitment in progress
Study duration per participant: up to 60 weeks
Study Title: « Randomized Phase II study of vedolizumab with or without therapeutic HIV vaccination (VAM) in people who started antiretroviral therapy during primary or chronic infection. »
The purpose of this study is to evaluate an antibody with or without a therapeutic HIV vaccine (VAM) in people living with HIV and on antiretroviral therapy. The term "therapeutic" here means a product "that may have a benefit" for people living with HIV. This study involves a maximum of 37 visits over a 60-week period. The study is being conducted in 4 phases:
Each study participant will be randomly assigned to one of three groups to receive either the active products or the placebos.